Acrux Ltd has released a press release.
Appendix 4E and Full Year Statutory Accounts FY25
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Licensing partnership in Saudi Arabia for Dapsone 5%, Gel
- Receipt of second advance for FY25 R&D Tax Incentive
- Dapsone 7.5%, Gel launched in the United States
- Acrux CEO and Managing Director appointment
- Acrux receives $1.73m advance on FY25 R&D Tax Incentive
Later from Acrux
- Received $3.04m RDTI rebate for FY25
- Acrux receives $0.4m advance on FY26 R&D Tax Incentive
- AGM Presentation and Address
- Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux